Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial

Trial Profile

Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms HAPIC
  • Sponsors Minapharm Pharmaceuticals
  • Most Recent Events

    • 15 Jan 2013 Planned number of patients changed from 2000 to 5000 as reported by ClinicalTrials.gov.
    • 03 Aug 2012 Actual initiation date (Aug 2012) added as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Status changed from not yet recruiting to recruiting added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top